FindTrial
Sign In

TP-102

BIOLOGICAL3 trials

Sponsors

Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A., Technophage, SA

Conditions

Acinetobacter InfectionDiabetic Foot InfectionDiabetic Foot UlcerDiabetic foot ulcers infected by Acinetobacter baumanniiPseudomonas Aeruginosa InfectionPseudomonas aeruginosa and /or Staphylococcus aureusStaphylococcus Aureus Infection

Phase 1

Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
CompletedNCT04803708
Technophage, SAAcinetobacter Infection, Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection +1
Start: 2021-03-22End: 2022-09-05Updated: 2022-10-04

Phase 2

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection
CompletedNCT05948592
Technophage, SADiabetic Foot Infection
Start: 2023-11-08End: 2025-12-19Updated: 2025-12-22
A Phase 2b Clinical Study to Evaluate the Safety and Efficacy of Topical Administration of Bacteriophage Therapy TP-102 in Patients with Diabetic Foot Infection
CompletedCTIS2023-507716-13-00
Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A.Diabetic foot ulcers infected by Acinetobacter baumannii, Pseudomonas aeruginosa and /or Staphylococcus aureus
End: 2025-12-19Target: 26Updated: 2025-08-18

Related Papers

Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers.
2024-12-3015 citations
RJX Improves Wound Healing in Diabetic Rats
Frontiers in Endocrinology2022-06-0213 citations